SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-003519
Filing Date
2022-11-21
Accepted
2022-11-21 17:16:16
Documents
69
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q scps-20220930x10q.htm   iXBRL 10-Q 1243673
2 EX-31.1 scps-20220930xex31d1.htm EX-31.1 13539
3 EX-31.2 scps-20220930xex31d2.htm EX-31.2 13952
4 EX-32.1 scps-20220930xex32d1.htm EX-32.1 7222
5 EX-32.2 scps-20220930xex32d2.htm EX-32.2 7318
  Complete submission text file 0001410578-22-003519.txt   5356910

Data Files

Seq Description Document Type Size
6 EX-101.SCH scps-20220930.xsd EX-101.SCH 57297
7 EX-101.CAL scps-20220930_cal.xml EX-101.CAL 25231
8 EX-101.DEF scps-20220930_def.xml EX-101.DEF 209501
9 EX-101.LAB scps-20220930_lab.xml EX-101.LAB 428299
10 EX-101.PRE scps-20220930_pre.xml EX-101.PRE 342657
63 EXTRACTED XBRL INSTANCE DOCUMENT scps-20220930x10q_htm.xml XML 681383
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39788 | Film No.: 221406700
SIC: 2834 Pharmaceutical Preparations